What is CG Oncology's conversion of stock issuance costs?

CG Oncology (CGON) reported conversion of stock issuance costs of $1.71M in Q4 2024.

What does conversion of stock issuance costs mean?

This metric represents the non-cash reclassification or conversion of previously accrued stock issuance costs into equity or other financial instruments. It reflects the final settlement of expenses incurred during capital raising activities that do not involve an immediate cash outflow. Monitoring this helps investors understand the total cost of equity financing beyond direct cash payments.

CG Oncology CGON Conversion Of Stock Issuance Costs

Conversion Of Stock Issuance Costs at other companies

Quantum Computing Inc.QUBT

$1.02M—

STU

StubHub Holdings, Inc.STUB

$2.06M—

Immunovant, Inc.IMVT

$126K-60.5%

NovaGold ResourcesNG

$0-100%

NNN REITNNN

$100K+17.6%

Crinetics PharmaceuticalsCRNX

$578K—

Other financials

Income statement

See full

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

See full

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

See full

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

See full

Market cap$5.8B+206%

Profitability

See full

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

See full

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept ck0001991792:ConversionOfStockIssuanceCosts.

The official record: CG Oncology’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's conversion of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CG Oncology's conversion of stock issuance costs?: CG Oncology (CGON) reported conversion of stock issuance costs of $1.71M in Q4 2024.
What does conversion of stock issuance costs mean?: This metric represents the non-cash reclassification or conversion of previously accrued stock issuance costs into equity or other financial instruments. It reflects the final settlement of expenses incurred during capital raising activities that do not involve an immediate cash outflow. Monitoring this helps investors understand the total cost of equity financing beyond direct cash payments.